Massachusetts compromises on weaker Medicaid drug price disclosures

Responding to a biopharma industry lobbying campaign, the Massachusetts legislature has dialed back drug price and cost disclosure requirements. The requirements are part of provisions in the state budget that

Read the full 303 word article

User Sign In